Get the Stockscreener App
11.84
1.81%
0.21
Bicara Therapeutics Inc stock is traded at $11.84, with a volume of 264.34K.
It is up +1.81% in the last 24 hours and up +3.41% over the past month.
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
See More
Previous Close:
$11.63
Open:
$11.63
24h Volume:
264.34K
Relative Volume:
0.36
Market Cap:
$646.02M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+1.72%
1M Performance:
+3.41%
6M Performance:
-8.92%
1Y Performance:
+0.00%
1-Day Range:
$11.53
$12.23
1-Week Range:
$10.64
$12.23
52-Week Range:
$7.80
$28.09
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Name
Bicara Therapeutics Inc
Sector
Industry
Phone
617-468-4219
Address
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Compare BCAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
11.84 | 625.84M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-23-25 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Apr-17-25 | Initiated | Wells Fargo | Underweight |
| Feb-06-25 | Initiated | Wedbush | Outperform |
| Dec-06-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
| Oct-08-24 | Initiated | Stifel | Buy |
| Oct-08-24 | Initiated | TD Cowen | Buy |
View All
Bicara Therapeutics Inc Stock (BCAX) Latest News
Bicara Therapeutics Inc. Trading Near Value Zone — Recovery AheadRecession Risk & Verified Technical Signals - thegnnews.com
Piper Sandler initiates coverage of oncology companies - MSN
Relay Therapeutics shares fall 2.45% intraday as Piper Sandler initiates coverage on Bicara Therapeutics. - AInvest
Piper Sandler initiates coverage of oncology companies (CGON:NASDAQ) - Seeking Alpha
Piper Sandler initiates Bicara Therapeutics stock with Overweight rating - Investing.com
When is the best time to exit Bicara Therapeutics Inc.July 2025 Macro Moves & Weekly Consistent Profit Watchlists - Newser
Promising Clinical Developments and Financial Stability Drive Buy Rating for Bicara Therapeutics - TipRanks
Does Bicara Therapeutics Inc. (BCAX) Have the Potential to Rally 187.73% as Wall Street Analysts Expect? - sharewise.com
Bicara Therapeutics Inc. Shares Could Surge 187.73% as Analysts Expect - AInvest
Bicara Therapeutics Inc. Stock Lags Behind Sector BenchmarksMarket Movement Recap & Intraday High Probability Setup Alerts - beatles.ru
Bicara Therapeutics Reports Q2 2025 Results and Progress - TipRanks
Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Bicara Therapeutics reports Q2 EPS (50c), consensus (54c) - MSN
Bicara Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Bicara Therapeutics and the Breakthrough Potential of Ficerafusp Alfa in Solid Tumors: A High-Conviction Biotech Investment in the Oncology Innovation Space - AInvest
Can Bicara Therapeutics Inc. sustain earnings growthStable Return Investment Forecast - thegnnews.com
Bicara Therapeutics BCAX 2025Q2 Earnings Preview Downside Ahead on Revenue Concerns - AInvest
Price Channel Expanding on Bicara Therapeutics Inc.’s ChartEarly Entry Picks Before News Breakout Reviewed - beatles.ru
Is Bicara Therapeutics Inc. stock overvalued or undervaluedStrong return on investment - Jammu Links News
How volatile is Bicara Therapeutics Inc. stock compared to the marketMaximize returns with disciplined trading - Jammu Links News
What analysts say about Bicara Therapeutics Inc. stockUnprecedented profits - Jammu Links News
What is Bicara Therapeutics Inc. company’s growth strategyMaximize gains with expert analysis - Jammu Links News
What are the latest earnings results for Bicara Therapeutics Inc.Exceptional stock performance - Jammu Links News
How does Bicara Therapeutics Inc. compare to its industry peersPhenomenal capital appreciation - Jammu Links News
Does Bicara Therapeutics Inc. stock perform well during market downturnsTake advantage of unprecedented market momentum - Jammu Links News
Is Bicara Therapeutics Inc. the Top Chart Pick This WeekEntry Points For Growing Stocks Identified by Models - beatles.ru
Is it the right time to buy Bicara Therapeutics Inc. stockBreakout Stocks Tips That Work - jammulinksnews.com
What institutional investors are buying Bicara Therapeutics Inc. stockLow Risk Recommendation That Work - Jammu Links News
Published on: 2025-07-31 05:01:42 - beatles.ru
Will Bicara Therapeutics Inc. Benefit From Broader Market BounceROI Boosting Trade Opportunity Calendar Published - metal.it
Bicara Therapeutics Inc. Inches Above Key Support — Safe to HoldWealth Building Stock Market Ideas Based on Momentum - metal.it
RSI Crosses Above 30 for Bicara Therapeutics Inc. — Reversal in SightGrowth Based Investment Plan Guidance Highlighted - metal.it
Bicara Therapeutics Inc. Shows Risk Reward Favoring UpsideEntry Alert Based on Volume Spikes Detected - metal.it
Will Bicara Therapeutics Inc. Recover After Recent DeclineConservative Entry for High Return Setup Backed - beatles.ru
When is Bicara Therapeutics Inc. stock expected to show significant growthSmart Portfolio Strategy For Beginners - Jammu Links News
How Bicara Therapeutics Inc. stock performs during market volatilityValue Investing Picks With Stability Outlined - metal.it
Bicara Therapeutics Inc. Stock Approaches Key Moving AverageROI Driven Equity Selection With Safety Emphasized - metal.it
Real time breakdown of Bicara Therapeutics Inc. stock performanceDaily Stock Forecast Powered by AI Tools - Newser
Why is Bicara Therapeutics Inc. stock attracting strong analyst attentionGain access to exclusive stock analysis - Jammu Links News
Bicara Therapeutics Inc. Stock Performance After Earnings: Historical InsightsDefensive Stock Picks with Upside - Newser
Bicara Therapeutics Inc Stock (BCAX) Financials Data
There is no financial data for Bicara Therapeutics Inc (BCAX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Bicara Therapeutics Inc Stock (BCAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Meisner Lara | Chief Legal Officer |
Jun 16 '25 |
Sale |
10.43 |
15,829 |
165,096 |
0 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):